Indaptus Therapeutics, Inc. (INDP) Stock Price & Analysis

Indaptus Therapeutics, Inc. (INDP) fell 5.78% to USD 2.61 as of July 25, 2026 at 08:50 UTC, according to Nexqual real-time market data.

INDP last closed at USD 2.77; the session ranged USD 2.57–2.88 on volume of 55,159 shares. Market capitalization is $347.76M, with a 52-week range of USD 0.92–10.57 (NCM). Source: Nexqual, July 25, 2026 at 08:50 UTC.

Key Statistics (as of July 25, 2026 at 08:50 UTC)

Technical Analysis (INDP)

Nexqual's technical model rates INDP "SELL" based on 1 bullish and 4 bearish signals across 125 daily candles, as of July 25, 2026 at 08:50 UTC.

Analyst Ratings (INDP)

Wall Street analysts rate INDP "None", per Nexqual as of July 25, 2026 at 08:50 UTC.

Earnings (INDP)

Recent Earnings History

Source: Nexqual, July 25, 2026 at 08:50 UTC.

Financials & Fundamentals (INDP)

Source: Nexqual, July 25, 2026 at 08:50 UTC.

Financial Health Score (INDP)

Nexqual rates Indaptus Therapeutics, Inc.'s overall financial health "Weak" across five dimensions, as of July 25, 2026 at 08:50 UTC.

Ownership (INDP)

Source: Nexqual, July 25, 2026 at 08:50 UTC.

Leadership (INDP)

Indaptus Therapeutics, Inc. is led by Junyi Dai (age 38), CEO & Chairman, per Nexqual as of July 25, 2026 at 08:50 UTC.

From Indaptus Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-17)

Key Strengths & Strategy (as disclosed to the SEC)

• In September 2025, we sold 520,000 shares of our common stock for aggregate gross proceeds of approximately $2.3 million.   June 2025 Convertible Note Financing   In June 2025, we completed a private placement, or the June 2025 Financing, of convertible notes to certain investors, including our then Chief Executive Officer, Jeffrey Meckler, in the aggregate principal amount of approximately $5.7 million and warrants to purchase shares of common stock.
• Regulation of Drugs and Biologics   In the United States, the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act (FDCA) and its implementing regulations, and biologics under the FDCA and the Public Health Service Act (PHSA) and its implementing regulations.
• FDA approval is required before any new unapproved drug or dosage form, including a new use of a previously approved drug, can be marketed in the United States.
• We have developed patented treatment methods (and associated patented compositions) for attenuation and killing of non-pathogenic, Gram-negative bacteria.

Partnerships

• We do not have any current plans to initiate a new clinical trial.   Recent Developments   Lazar Investment Transaction   On December 22, 2025, we entered into the Purchase Agreement with Mr.
• LLC ("Wainwright"), which was amended on September 1, 2022, relating to the offer and sale of shares of our common stock having an aggregate offering price of up to $6.3 million.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 08:50 UTC. This page is informational and not investment advice.